128 related articles for article (PubMed ID: 8387768)
1. The autocrine function of vasoactive intestinal peptide on human neuroblastoma cell growth and differentiation.
Pence JC; Shorter NA
Arch Surg; 1993 May; 128(5):591-5. PubMed ID: 8387768
[TBL] [Abstract][Full Text] [Related]
2. Autoregulation of neuroblastoma growth by vasoactive intestinal peptide.
Pence JC; Shorter NA
J Pediatr Surg; 1992 Aug; 27(8):935-43; discussion 944. PubMed ID: 1328588
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma.
O'Dorisio MS; Fleshman DJ; Qualman SJ; O'Dorisio TM
Regul Pept; 1992 Feb; 37(3):213-26. PubMed ID: 1313595
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid enhances VIP receptor expression and responsiveness in human neuroblastoma cell, SH-SY5Y.
Waschek JA; Muller JM; Duan DS; Sadée W
FEBS Lett; 1989 Jul; 250(2):611-4. PubMed ID: 2546814
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
6. Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1.
Balster DA; O'Dorisio MS; Albers AR; Park SK; Qualman SJ
Regul Pept; 2002 Nov; 109(1-3):155-65. PubMed ID: 12409228
[TBL] [Abstract][Full Text] [Related]
7. Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell line.
Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM; Cooper CW
Endocrinology; 1992 Sep; 131(3):1188-94. PubMed ID: 1324153
[TBL] [Abstract][Full Text] [Related]
8. In vitro differentiation of human neuroblastoma cells caused by vasoactive intestinal peptide.
Pence JC; Shorter NA
Cancer Res; 1990 Aug; 50(16):5177-83. PubMed ID: 2379178
[TBL] [Abstract][Full Text] [Related]
9. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor.
Sreedharan SP; Patel DR; Huang JX; Goetzl EJ
Biochem Biophys Res Commun; 1993 Jun; 193(2):546-53. PubMed ID: 8390245
[TBL] [Abstract][Full Text] [Related]
10. Pituitary adenylate cyclase activating peptide and vasoactive intestinal polypeptide: differentiation effects on human neuroblastoma NB-OK-1 cells.
Hoshino M; Li M; Zheng LQ; Suzuki M; Mochizuki T; Yanaihara N
Neurosci Lett; 1993 Sep; 159(1-2):35-8. PubMed ID: 7903438
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide: a growth promoter in neuroblastoma cells.
Wollman Y; Lilling G; Goldstein MN; Fridkin M; Gozes I
Brain Res; 1993 Oct; 624(1-2):339-41. PubMed ID: 8252411
[TBL] [Abstract][Full Text] [Related]
12. Receptor-mediated actions of growth hormone releasing factor on granulosa cell differentiation.
Moretti C; Bagnato A; Solan N; Frajese G; Catt KJ
Endocrinology; 1990 Nov; 127(5):2117-26. PubMed ID: 2171907
[TBL] [Abstract][Full Text] [Related]
13. Functional vasoactive intestinal polypeptide (VIP) receptors in human neuroblastoma subclones that contain VIP precursor mRNA and release VIP-like substances.
Muller JM; Lolait SJ; Yu VC; Sadée W; Waschek JA
J Biol Chem; 1989 Mar; 264(7):3647-50. PubMed ID: 2537287
[TBL] [Abstract][Full Text] [Related]
14. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP.
Lutz EM; Ronaldson E; Shaw P; Johnson MS; Holland PJ; Mitchell R
Mol Cell Neurosci; 2006 Feb; 31(2):193-209. PubMed ID: 16226889
[TBL] [Abstract][Full Text] [Related]
15. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 2. Effect of VIP on cAMP production and on cell-surface VIP-binding sites.
Martin JM; Luis J; Marvaldi J; Pichon J; Pic P
Eur J Biochem; 1989 Mar; 180(2):435-9. PubMed ID: 2538331
[TBL] [Abstract][Full Text] [Related]
16. Interaction between catecholamines and vasoactive intestinal peptide in cultured astrocytes.
Hansson E; Rönnbäck L
Neuropharmacology; 1988 Mar; 27(3):295-300. PubMed ID: 2836754
[TBL] [Abstract][Full Text] [Related]
17. Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines.
Bellan C; Pic P; Marvaldi J; Fantini J; Pichon J
Second Messengers Phosphoproteins; 1991; 13(4):163-71. PubMed ID: 1667418
[TBL] [Abstract][Full Text] [Related]
18. Role of sulfhydryl groups in the binding of vasoactive intestinal peptide to its receptor on murine lymphocytes.
Ottaway CA
J Neuroimmunol; 1992 Jul; 39(1-2):49-56. PubMed ID: 1320058
[TBL] [Abstract][Full Text] [Related]
19. A new vasoactive intestinal peptide antagonist discriminates VIP receptors on guinea pig trachea and human neuroblastoma cells.
Leroux F; Goossens JF; Pommery N; Hénichart JP
Regul Pept; 1994 Jul; 52(2):119-28. PubMed ID: 7972935
[TBL] [Abstract][Full Text] [Related]
20. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle.
Chakder S; Rattan S
J Pharmacol Exp Ther; 1993 Jul; 266(1):392-9. PubMed ID: 8392560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
